Company news
Kaken Pharmaceutical Co., Ltd. news in 2025
Kaken Pharmaceutical Co., Ltd.'s news releases, calls and decks from 2025, newest first.
KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema
December 22, 2025
Kaken Pharmaceutical: Consolidated Financial Results for the Six-Months Period of Fiscal 2025【Script】
November 18, 2025
Numab Therapeutics and Kaken Pharmaceutical Announce Licensing and Co-development Agreement for Multispecific Antibody NM81 in Inflammatory Bowel Disease (IBD)
November 13, 2025
Kaken Pharmaceutical: Consolidated Financial Results for the Six Months Period of Fiscal 2025 (Six Month Period Ended September 30, 2025)
November 10, 2025
Supplementary Financial Information of Consolidated Financial Results for the Six Months Period Ended September 30, 2025
November 10, 2025
Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
August 12, 2025
Supplementary Financial Information of Consolidated Financial Results for the Three Months Period June 30, 2025
August 7, 2025
Kaken Pharmaceutical: Consolidated Financial Results for the Three Months Period of Fiscal 2025 (Three Month Period Ended June 30, 2025)
August 7, 2025
Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan
August 6, 2025
Kaken Pharmaceutical: Consolidated Financial Results for the Fiscal Year 2024【Script of the briefing session】
May 19, 2025
Kaken Pharmaceutical: Consolidated Financial Results for the Fiscal Year 2024
May 12, 2025
Supplementary Financial Information of Financial Statements Fiscal 2024
May 12, 2025
Kaken Pharmaceutical: Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 Supplementary Financial Information
May 12, 2025
Reference Data of Financial Statements for the 3Q of Fiscal 2024
February 6, 2025